Market Data
Market Cap₹1,737.25 Cr.
52W High₹849.05
Current Price₹535.55
52W Low₹502.2
Down from 52W High36.9 %
Face Value₹5
Performance
ROCE11.44 %
ROE9.94 %
EPS (TTM)₹5.1
EPS Prev Qtr₹12.86
EPS Last Year₹7.38
EBITDA Qtr₹30.03 Cr.
Book Value₹303
Financial Health
Debt/Equity0.5
Debt/Profit5.03
Total Assets₹1,823.716 Cr.
Dividend Yield0.37 %
Promoter Holding27.11 %
Earning Power6.67 %
Valuation
Stock P/E17.82
Industry P/E40.99
Price to Book1.77
Price to Sales2.13
Graham Number₹452.38
Key Metrics
__derived
1
Face Value
₹5
About Krsnaa Diagnostics Ltd
Healthcare · Healthcare
Krsnaa Diagnostics Ltd is listed on NSE in the Healthcare / Healthcare sector. Face value ₹5. Market cap ₹1,737.25 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company has a healthy ROCE of 16.05%, indicating efficient use of capital.
- The company maintains a low debt-to-equity ratio of 0.19, suggesting a conservative capital structure.
- The company has a positive net profit of ₹97.47 Cr, showing profitability.
Weaknesses
- The dividend yield is low at 0.37%, which may not attract income-focused investors.
- The P/E ratio of 18.01 may indicate that the stock is relatively expensive compared to its earnings.
- The P/B ratio of 1.99 suggests that the market values the company close to its book value, leaving limited upside potential if the market perceives the asset base as fully valued.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Apollo Hospitals Enterprise Ltd | - | 60.97 | ₹1,27,421.96 Cr | 0.23% | ₹2,172 Cr | - | ₹26,429.9 Cr | - | 22.05% | 0.6 |
| Max Healthcare Institute Ltd | - | 66.77 | ₹97,411.97 Cr | 0.2% | ₹1,457.4 Cr | - | ₹8,712.05 Cr | - | 14.38% | 0.27 |
| Manipal Health Enterprises Ltd | - | - | ₹94,970.23 Cr | - | - | - | - | - | - | 1.25 |
| Aster DM Quality Care Ltd | - | 121 | ₹65,183.66 Cr | 0.4% | ₹362.82 Cr | - | ₹4,876.03 Cr | - | 12.95% | 0.17 |
| Fortis Healthcare Ltd | - | 59.91 | ₹62,782.32 Cr | 0.12% | ₹1,070.21 Cr | - | ₹9,506.15 Cr | - | 13.34% | 0.29 |
| Global Health Ltd | - | 69.27 | ₹38,550.84 Cr | - | ₹552.33 Cr | - | ₹4,683.41 Cr | - | 21.87% | 0.1 |
| Narayana Hrudayalaya Ltd | - | 45.26 | ₹37,159.95 Cr | - | ₹816.55 Cr | - | ₹9,072.4 Cr | - | 13.65% | 1.07 |
| Dr Lal Pathlabs Ltd | - | 46.81 | ₹32,548.55 Cr | 1.26% | ₹546.3 Cr | - | ₹2,890.8 Cr | - | 29.55% | 0 |
| Krishna Institute of Medical Sciences Ltd | - | 150.24 | ₹32,180.9 Cr | - | ₹194.4 Cr | - | ₹4,212.5 Cr | - | 9.66% | 1.44 |
| Poly Medicure Ltd | - | 52.64 | ₹16,587.48 Cr | 0.21% | ₹312.92 Cr | - | ₹1,997.43 Cr | - | 15.07% | 0.06 |
| Dr Agarwals Health Care Ltd | - | 107.57 | ₹15,991.79 Cr | - | ₹185.1 Cr | - | ₹2,206.68 Cr | - | 16.46% | 0.08 |
| Vijaya Diagnostic Centre Ltd | - | 82.27 | ₹15,431.94 Cr | 0.13% | ₹187.49 Cr | - | ₹857.13 Cr | - | 36.21% | 0 |
| Syngene International Ltd | - | 68.32 | ₹15,167.87 Cr | 0.33% | ₹221 Cr | - | ₹3,600.2 Cr | - | 6.95% | 0 |
| Indegene Ltd | - | 36.68 | ₹14,769.29 Cr | 0.37% | ₹400.9 Cr | - | ₹3,812.8 Cr | - | 17.45% | 0 |
| Rainbow Childrens Medicare Ltd | - | 48.85 | ₹13,947.12 Cr | 0.25% | ₹290.28 Cr | - | ₹1,820.14 Cr | - | 27.05% | 0 |
| Molbio Diagnostics Ltd | - | - | ₹13,924.73 Cr | - | - | - | - | - | - | 0.35 |
| Park Medi World Ltd | - | 38.3 | ₹11,945.05 Cr | - | ₹296.75 Cr | - | ₹1,756.29 Cr | - | 19.17% | 0.11 |
| Metropolis Healthcare Ltd | - | 24.51 | ₹11,863.54 Cr | 0.87% | ₹202.82 Cr | - | ₹1,710 Cr | - | 19.8% | 0.01 |
| Yatharth Hospital & Trauma Care Services Ltd | - | 58.5 | ₹10,596.57 Cr | - | ₹174.45 Cr | - | ₹1,334.1 Cr | - | 11.7% | 0.14 |
| Healthcare Global Enterprises Ltd | - | 446.68 | ₹10,336.94 Cr | - | ₹33.26 Cr | - | ₹2,627.35 Cr | - | 9.41% | 0.68 |
Quarterly Results
📊 Jun 2026: Revenue grew 22.0% YoY, Profit fell 19.3% YoY
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 192.98 | 205.99 | 181.2 | 192.6 | 235.53 |
| ↳ QoQ Growth | - | +6.7% | -12.0% | +6.3% | +22.3% |
| Expenses | 163.22 | 170.42 | 157.42 | 160.31 | 205.51 |
| Operating Profit | 29.76 | 35.57 | 23.79 | 32.29 | 30.03 |
| OPM % | 15.42% | 17.27% | 13.13% | 16.77% | 12.75% |
| Other Income | 3.95 | 4.17 | 3.77 | 31.5 | 7.24 |
| Interest | 6.3 | 8.19 | 7.79 | 12.08 | 14.83 |
| Depreciation | 21.63 | 23.59 | 22.66 | 22.59 | 27.96 |
| EBITDA | 51.39 | 59.16 | 46.45 | 54.88 | 57.99 |
| EBITDA Margin % | 26.63% | 28.72% | 25.63% | 28.49% | 24.62% |
| Profit Before Tax | 27.42 | 31.56 | 19.68 | 51.7 | 22.44 |
| Tax % | 25.16% | 24.14% | 22.56% | 19.3% | 26.25% |
| Net Profit | 20.52 | 23.95 | 15.25 | 41.72 | 16.55 |
| ↳ QoQ Growth | - | +16.7% | -36.3% | +173.6% | -60.3% |
| EPS | 6.35 | 7.38 | 4.72 | 12.86 | 5.1 |
Profit & Loss
| Mar 2026 | TTM | |
|---|---|---|
| Sales | 772.77 | 815.32 |
| Expenses | 651.37 | 693.66 |
| Operating Profit | 121.41 | 121.68 |
| OPM % | 15.71% | 14.92% |
| Other Income | 43.39 | 46.68 |
| Interest | 34.36 | 42.89 |
| Depreciation | 90.47 | 96.8 |
| Profit Before Tax | 130.36 | 125.38 |
| Tax % | 22.2% | 22.28% |
| Net Profit | 101.44 | 97.47 |
| EPS | 31.31 | 30.06 |
Compounded Sales Growth
10Y
-
5Y
-
3Y
-
TTM
-
Compounded Profit Growth
10Y
-
5Y
-
3Y
-
TTM
-
Stock Price CAGR
10Y
-
5Y
-
3Y
-
1Y
-30.43%
Return on Equity
10Y
-
5Y
-
3Y
-
Last Year
9.94%
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 16.15 | 16.219 |
| Reserves | 866.63 | 964.169 |
| Borrowings | 203.53 | 490.51 |
| Other Liabilities | 195.29 | 352.82 |
| Total Liabilities | 1281.6 | 1823.716 |
| Fixed Assets | 667.43 | 656.468 |
| CWIP | 2.96 | 208.072 |
| Investments | 31.54 | 57.43 |
| Other Assets | 579.67 | 901.75 |
| Total Assets | 1281.6 | 1823.716 |
Cash Flows
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from Operating Activity | 87.327 | 143.098 |
| Cash from Investing Activity | -99.609 | -395.987 |
| Cash from Financing Activity | 13.753 | 279.265 |
| Net Cash Flow | 1.471 | 26.376 |
Ratios
| Mar 2026 | |
|---|---|
| Debtor Days | - |
| Inventory Days | - |
| Days Payable | - |
| Cash Conversion Cycle | - |
| Working Capital Days | 629.71 |
| ROCE % | 9.11% |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 27.11% | 27.11% | 27.11% | 27.11% |
| FIIs % | 3.67% | 4.17% | 3.91% | 4.28% |
| DIIs % | 14.96% | 13.86% | 13.89% | 14.51% |
| Public % | 27.4% | 27.84% | 28.68% | 27.85% |
| No. of Shareholders | 52,117 | 52,380 | 53,022 | 53,625 |
Major Shareholders (>1%)
- Rajendra Khivraj MuthaPromoter and Promoter Group24.75%
- Phi Capital Trust - Phi Capital Growth Fund - IPublic Shareholding15.37%
- Tata Mutual Fund - Tata Small Cap FundPublic Shareholding8.04%
- Krsna Diagnostics (mumbai) Private LimitedPromoter and Promoter Group2.36%
As of 2026-06-30View all shareholders →